Viz.ai Wins Gold Edison Award™ for Advancing AI-Driven Clinical Workflows to Improve Hemorrhage Care

Fourth consecutive Edison Award underscores Viz.ai’s role as the infrastructure layer enabling AI-driven decision-making at the point of care

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it won the Gold Edison Award 2026 for its AI-powered Viz Hemorrhage solution. This marks the company’s fourth Edison Award and reinforces Viz.ai’s leadership in building the agentic infrastructure that enables artificial intelligence to operate directly within hospitals.

Viz.ai was recognized in the Health, Medical & Biotech category for its groundbreaking ability to identify and characterize hemorrhagic conditions, including intracranial hemorrhage and subdural hematoma, while seamlessly connecting care teams through a unified workflow. By combining AI-powered imaging analysis with automated measurements and care coordination, the solution helps teams quickly identify suspected hemorrhages, quantify the collections, align on next steps, and support timely, life-saving treatment. More than a standalone AI application, Viz Hemorrhage is a solution that brings together four FDA-cleared algorithms, reflecting a broader shift toward AI solutions that integrate data, intelligence, and coordination into a single operational layer.

“AI in healthcare only delivers value when it is embedded into the workflows where care decisions are made. Our fourth Edison Award reflects the evolution of AI in healthcare, from individual algorithms to agentic AI infrastructure that supports real-world clinical work,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “With Viz Hemorrhage, we’re embedding intelligence directly into clinical workflows, enabling care teams to align around shared data and act within a connected system.”

Viz Hemorrhage leverages artificial intelligence to analyze medical imaging in real time, automatically identifying suspected hemorrhagic conditions and providing Al-driven characterization of imaging, and notifying the appropriate specialists through the Viz.ai enterprise platform. By embedding AI directly into clinical workflows, the platform may transform imaging data into coordinated action, which may help inform decision-making and care alignment. Deployed across 2,000 hospitals, Viz.ai serves as a clinical infrastructure layer, enabling scalable, agentic workflows that extend across service lines.

This recognition builds on Viz.ai’s prior three Edison Awards across neurology, pulmonary, and cardiology, demonstrating the platform’s ability to extend agentic clinical infrastructure consistently across multiple clinical domains.

The Edison Awards honor excellence in innovation, recognizing the most impactful new products and services across industries. Finalists are evaluated by a panel of more than 2,000 senior executives, academics, and innovation leaders. Gold represents the highest distinction awarded.

For more information on Viz Hemorrhage, please visit viz.ai/hemorrhage.

About Viz.ai

Viz.ai is the leader in AI-powered care coordination and clinical workflow solutions, deployed in 2,000 hospitals across the United States and trusted by leading life sciences companies. Its platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.